Common drug lithium may put brakes on Parkinson's, early hints suggest
NCT ID NCT06592014
Summary
This study continues testing if low-dose lithium can slow Parkinson's disease progression. It enrolls 35 patients who have already finished a prior 24-week lithium trial. Researchers will adjust each person's lithium dose to reach a specific target level in the blood for another 24 weeks, then check for changes in brain scans and blood tests that might indicate the disease is slowing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UBMD Neurology
Williamsville, New York, 14221, United States
Conditions
Explore the condition pages connected to this study.